Rationale in support of the use of selective dopamine D3 receptor antagonists for the pharmacotherapeutic management of substance use disorders

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 2, 2013, Pages 167-176

  Heidbreder, Christian ^a  

^a RECKITT BENCKISER   (United Kingdom)

Author keywords

Addiction; D3 receptor; Dopamine; Impulse control disorders; Selective antagonists; Substance use disorders

Indexed keywords

[N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUT 2 ENYL] 4 (PYRIDIN 2 YL)BENZAMIDE]; [N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUTYL] 9H FLUORENE 2 CARBOXAMIDE]; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; GSK 598809; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; N [4 [2 (8 CYANO 1,3A,4,9B TETRAHYDRO 1 BENZOPYRANO[3,4 C]PYRROL 2(3H) YL)ETHYL]PHENYL]ACETAMIDE; NGB 2904; PG 01037; SB 414796; UNCLASSIFIED DRUG;

ADAPTATION; ALCOHOLISM; ASSOCIATION; COCAINE DEPENDENCE; CORPUS STRIATUM; DISEASE MODEL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SEEKING BEHAVIOR; DRUG SELF ADMINISTRATION; DRUG SYNTHESIS; DRUG USE; GLOBUS PALLIDUS; HUMAN; MESENCEPHALON; MESOLIMBIC DOPAMINERGIC SYSTEM; NONHUMAN; OPIATE ADDICTION; PATHOPHYSIOLOGY; REINFORCEMENT; REVIEW; STRESS; SUBSTANCE ABUSE; TOBACCO DEPENDENCE;

ANIMALS; DOPAMINE ANTAGONISTS; HUMANS; RECEPTORS, DOPAMINE D3; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84873629162     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-012-0803-6     Document Type: Review

References (109)

1. Achat-Mendes C, Grundt P, Cao J, Platt DM, Newman AH, Spealman RD (2010) Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys. J Pharmacol Exp Ther 334:556-565
2. 3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 28:1272-1280
3. 3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse 48:154-156
4. Austin NE, Baldwin SJ, Cutler L, Deeks N, Kelly PJ, Nash M, Shardlow CE, Stemp G, Thewlis K, Ayrton A, Jeffrey P (2001) Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. Xenobiotica 31:677-686
5. Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J, Wilkins D, Selby P, George TP, Zack M, Furukawa Y, McCluskey T, Wilson AA, Kish SJ (2012) Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci 32:1353-1359
6. 2 dopamine receptor cDNA. Nature 336:783-787
7. Campiani G, Butini S, Trotta F, Fattorusso C, Catalanotti B, Aiello F, Gemma S, Nacci V, Novellino E, Stark JA, Cagnotto A, Fumagalli E, Carnovali F, Cervo L, Mennini T (2003) Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. J Med Chem 46:3822-3839
8. Cervo L, Cocco A, Petrella C, Heidbreder CA (2007) Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat. Int J Neuropsychopharmacol 10:167-181
9. Chourbaji S, Brandwein C, Vogt MA, Dormann C, Mueller R, Drescher KU, Gross G, Gass P (2008) Dopamine receptor 3 (D3) knockout mice show regular emotional behaviour. Pharmacol Res 58:302-307
10. Clément P, Pozzato C, Heidbreder C, Alexandre L, Giuliano F, Melotto S (2009) Delay of ejaculation induced by SB-277011, a selective dopamine D3 receptor antagonist, in the rat. J Sex Med 6:980-988
11. Cole DM, Beckmann CF, Searle GE, Plisson C, Tziortzi AC, Nichols TE, Gunn RN, Matthews PM, Rabiner EA, Beaver JD (2011) Orbitofrontal connectivity with resting-state networks is associated with midbrain dopamine D3 receptor availability. Cereb Cortex. doi: 10.1093/cercor/bhr354
12. Dalley JW, Cardinal RN, Robbins TW (2004) Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 28:771-784
13. Day M, Bain E, Marek G, Saltarelli M, Fox GB (2010) D3 receptor target engagement in humans with ABT-925 using [11C](+)-PHNO PET. Int J Neuropsychopharmacol 13:291-292
14. Di Ciano P (2008) Drug seeking under a second-order schedule of reinforcement depends on dopamine D3 receptors in the basolateral amygdala. Behav Neurosci 122:129-139
15. Di Ciano P, Underwood RJ, Hagan JJ, Everitt BJ (2003) Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology 28:329-338
16. Epstein DH, Preston KL, Stewart J, Shaham Y (2006) Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacol (Berl) 189:1-16
17. Field M, Cox WM (2008) Attentional bias in addictive behaviors: a review of its development, causes, and consequences. Drug Alcohol Depend 97:1-20
18. Gál K, Gyertyán I (2003) Targeting the dopamine D3 receptor cannot influence continuous reinforcement cocaine self-administration in rats. Brain Res Bull 61:595-601
19. Gál K, Gyertyán I (2006) Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats. Drug Alcohol Depend 81:63-70
20. 11C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 66:489-500
21. Gilbert J (2004) Proceedings of the 14th Annual Symposium of the International Cannabinoid Research Society (ICRS), June 22nd-27th, Paestum (Italy)
22. 3 receptors. Synapse 57:17-28
23. Ginovart N, Willeit M, Rusjan P, Graff A, Bloomfield PM, Houle S, Kapur S, Wilson AA (2007) Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 27:857-871
24. Glickstein SB, Desteno DA, Hof PR, Schmauss C (2005) Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cereb Cortex 15:1016-1024
25. Graff-Guerrero A, Willeit M, Ginovart N, Mamo D, Mizrahi R, Rusjan P, Vitcu I, Seeman P, Wilson AA, Kapur S (2008) Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum Brain Mapp 29:400-410
26. Graff-Guerrero A, Redden L, Abi-Saab W, Katz DA, Houle S, Barsoum P, Bhathena A, Palaparthy R, Saltarelli MD, Kapur S (2010) Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol 13:273-287
27. Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH (2005) Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem 48:839-848
28. Gyertyán I, Gál K (2003) Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference. Neuroreport 14:93-98
29. Gyertyán I, Sághy K (2007) The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur J Pharmacol 572:171-174
30. Heidbreder CA, Newman AH (2010) Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann NY Acad Sci 1187:4-34
31. 3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Rev 49:77-105
32. 3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice. Addict Biol 12:35-50
33. Hester R, Lubman DI, Yücel M (2010) The role of executive control in human drug addiction. Curr Top Behav Neurosci 3:301-318
34. Higley AE, Kiefer SW, Li X, Gaál J, Xi ZX, Gardner EL (2011a) Dopamine D(3) receptor antagonist SB-277011A inhibits methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking in rats. Eur J Pharmacol 1(659):187-192
35. Higley AE, Spiller K, Grundt P, Newman AH, Kiefer SW, Xi ZX, Gardner EL (2011b) PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats. J Psychopharmacol 25:263-273
36. Hyman SE (2005) Addiction: a disease of learning and memory. Am J Psychiatry 162:1414-1422
37. Khaled MA, Farid Araki K, Li B, Coen KM, Marinelli PW, Varga J, Gaál J, Le Foll B (2010) The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. Int J Neuropsychopharmacol 13:181-190
38. 2 receptor sites. Synapse 65:467-478
39. Lacroix LP, Hows ME, Shah AJ, Hagan JJ, Heidbreder CA (2003) Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 28:839-849
40. Lacroix LP, Ceolin L, Zocchi A, Varnier G, Garzotti M, Curcuruto O, Heidbreder CA (2006) Selective dopamine D(3) receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases. J Neurosci Methods 157:25-31
41. Laszy J, Laszlovszky I, Gyertyán I (2005) Dopamine D3 receptor antagonists improve the learning performance of memory-impaired rats. Psychopharmacology 179:567-575
42. Le Foll B, Francès H, Diaz J, Schwartz JC, Sokoloff P (2002) Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur J Neurosci 15:2016-2026
43. Le Foll B, Diaz J, Sokoloff P (2003a) Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse 47:176-183
44. Le Foll B, Schwartz JC, Sokoloff P (2003b) Disruption of nicotine conditioning by dopamine D3 receptor ligands. Mol Psychiatry 8:225-230
45. Loiseau F, Millan MJ (2009) Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists. Eur Neuropsychopharmacol 19:23-33
46. 3 receptor antagonist. J Med Chem 46:4952-4964
47. Martelle JL, Claytor R, Ross JT, Reboussin BA, Newman AH, Nader MA (2007) Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3 dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 321:573-582
48. Martinez D, Narendran R, Foltin RW, Slifstein M, Hwang DR, Broft A, Huang Y, Cooper TB, Fischman MW, Kleber HD, Laruelle M (2007) Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 164:622-629
49. Mash DC (1997) D3 receptor binding in human brain during cocaine overdose. Mol Psychiatry 2:5-6
50. Mash DC, Staley JK (1999) D3 dopamine and kappa opioid receptor alterations in human brain of cocaine-overdose victims. Ann NY Acad Sci 877:507-522
51. Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Di Marzo V, Drago F (2010) Enhanced cognitive performance of dopamine D3 receptor knock-out mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems. Pharmacol Res 61:531-536
52. Micheli F (2011) Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective. ChemMedChem 6:1152-1162
53. Micheli F, Bonanomi G, Blaney FE, Braggio S, Capelli AM, Checchia A, Curcuruto O, Damiani F, Fabio RD, Donati D, Gentile G, Gribble A, Hamprecht D, Tedesco G, Terreni S, Tarsi L, Lightfoot A, Stemp G, Macdonald G, Smith A, Pecoraro M, Petrone M, Perini O, Piner J, Rossi T, Worby A, Pilla M, Valerio E, Griffante C, Mugnaini M, Wood M, Scott C, Andreoli M, Lacroix L, Schwarz A, Gozzi A, Bifone A, Ashby CR Jr, Hagan JJ, Heidbreder C (2007) 1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists. J Med Chem 50:5076-5089
54. Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Dubuffet T, Lavielle G (2000a) S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293:1048-1062
55. Millan MJ, Dekeyne A, Rivet JM, Dubuffet T, Lavielle G, Brocco M (2000b) S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293:1063-1073
56. Millan MJ, Di Cara B, Dekeyne A, Panayi F, De Groote L, Sicard D, Cistarelli L, Billiras R, Gobert A (2007) Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem 100:1047-1061
57. Millan MJ, Mannoury la Cour C, Novi F, Maggio R, Audinot V, Newman-Tancredi A, Cussac D, Pasteau V, Boutin JA, Dubuffet T, Lavielle G (2008a) S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]- benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. J Pharmacol Exp Ther 324:587-599
58. Millan MJ, Svenningsson P, Ashby CR Jr, Hill M, Egeland M, Dekeyne A, Brocco M, Di Cara B, Lejeune F, Thomasson N, Munoz C, Mocaër E, Crossman A, Cistarelli L, Girardon S, Iob L, Veiga S, Gobert A (2008b) S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c] pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. J Pharmacol Exp Ther 324:600-611
59. Millan MJ, Loiseau F, Dekeyne A, Gobert A, Flik G, Cremers TI, Rivet JM, Sicard D, Billiras R, Brocco M (2008c) S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a, 4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J Pharmacol Exp Ther 324:1212-1226
60. Millan MJ, Buccafusco JJ, Loiseau F, Watson DJ, Decamp E, Fone KC, Thomasson-Perret N, Hill M, Mocaer E, Schneider JS (2010) The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol 13:1035-1051
61. 1 receptor linked to adenylyl cyclase activation. Proc Natl Acad Sci U S A 87:6723-6727
62. Mugnaini M, Iavarone L, Cavallini P, Griffante C, Oliosi B, Savoia C, Beaver J, Rabiner EA, Micheli F, Heidbreder C, Andorn A, Merlo Pich E, Bani M (2012) Occupancy of brain dopamine D(3) receptors and drug craving: a translational approach. Neuropsychopharmacol 12. doi: 10.1038/npp.2012.171
63. Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, Scher E, Reeder S, Rabiner E, Laruelle M (2006) Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 60:485-495
64. Narendran R, Frankle WG, Mason NS, Laymon CM, Lopresti BJ, Price JC, Kendro S, Vora S, Litschge M, Mountz JM, Mathis CA (2009) Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [(11)C]-N-propyl-norapomorphine: preliminary evaluation and reproducibility studies. Synapse 63:574-584
65. Neisewander JL, Fuchs RA, Tran-Nguyen LT, Weber SM, Coffey GP, Joyce JN (2004) Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior. Neuropsychopharmacology 29:1479-1487
66. Orio L, Wee S, Newman AH, Pulvirenti L, Koob GF (2010) The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access. Addict Biol 15:312-323
67. 3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol 9:585-602
68. Peng XQ, Ashby CR Jr, Spiller K, Li X, Li J, Thomasson N, Millan MJ, Mocaër E, Muńoz C, Gardner EL, Xi ZX (2008) The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats. Neuropharmacology 56:752-760
69. Rabiner EA, Laruelle M (2010) Imaging the D3 receptor in humans in vivo using [11C](+)-PHNO positron emission tomography (PET). Int J Neuropsychopharmacol 13:289-290
70. Rabiner EA, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R, Diwan M, Wilson AA, McCormick P, Gentile G, Gunn RN, Laruelle MA (2009) In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mice. Synapse 63:782-793
71. 3 receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294:1154-1165
72. Rice OV, Patrick J, Schonhar CD, Ning H, Ashby CR Jr (2012a) The effects of the preferential dopamine D(3) receptor antagonist S33138 on ethanol binge-drinking in C57BL/6J mice. Synapse 23. doi: 10.1002/syn.21575
73. Rice OV, Gardner EL, Heidbreder CA, Ashby CR Jr (2012b) The acute administration of the selective dopamine D(3) receptor antagonist SB-277011A reverses conditioned place aversion produced by naloxone precipitated withdrawal from acute morphine administration in rats. Synapse 66:85-87
74. 3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats. Eur J Pharmacol 559:173-179
75. Sato K, Ueda H, Okumura F, Misu Y (1994) 6-OHDA-induced lesion of the nigrostriatal dopaminergic neurons potentiates the inhibitory effect of 7-OHDPAT, a selective D3 agonist, on acetylcholine release during striatal microdialysis in conscious rats. Brain Res 655:233-236
76. Schwarz AJ, Gozzi A, Reese T, Heidbreder CA, Bifone A (2007) Pharmacological modulation of functional connectivity: the correlation structure underlying the phMRI response to d-amphetamine modified by selective dopamine D3 receptor antagonist SB277011A. Magn Reson Imaging 25:811-820
77. Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M, Mugnaini M, Griffante C, Wilson AA, Merlo-Pich E, Houle S, Gunn R, Rabiner EA, Laruelle M (2010) Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 68:392-399
78. Segal DM, Moraes CT, Mash DC (1997) Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Res Mol Brain Res 45:335-339
79. Sigala S, Missale C, Spano P (1997) Opposite effects of dopamine D2 and D3 receptors on learning and memory in the rat. Eur J Pharmacol 336:107-12
80. Siuciak JA, Fujiwara RA (2004) The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors. Psychopharmacol (Berl) 175:163-169
81. Sofuoglu M, Devito EE, Waters AJ, Carroll KM (2013) Cognitive enhancement as a treatment for drug addictions. Neuropharmacology 64:452-463
82. 3) as a target for neuroleptics. Nature 347:146-151
83. Song R, Yang RF, Wu N, Su RB, Li J, Peng XQ, Li X, Gaál J, Xi ZX, Gardner EL (2012) YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. Addict Biol 17:259-273
84. Spangler R, Goddard NL, Avena NM, Hoebel BG, Leibowitz SF (2003) Elevated D3 dopamine receptor mRNA in dopaminergic and dopaminoceptive regions of the rat brain in response to morphine. Brain Res Mol Brain Res 111:74-83
85. Spiller K, Xi ZX, Peng XQ, Newman AH, Ashby CR Jr, Heidbreder C, Gaál J, Gardner EL (2008) The selective dopamine D(3) receptor antagonists SB-277011A and NGB 2904 and the putative partial D(3) receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacol (Berl) 196:533-542
86. Staley JK, Mash DC (1996) Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 16:6100-6106
87. 3 receptor antagonist with high oral bioavailability and CNS penetration in the rat. J Med Chem 43:1878-1885
88. 1. Nature 350:614-619
89. Swain SN, Beuk J, Heidbreder CA, Beninger RJ (2008) Role of dopamine D(3) receptors in the expression of conditioned fear in rats. Eur J Pharmacol 579:167-176
90. 3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats. Pharmacol Biochem Behav 81:190-197
91. Thanos PK, Michaelides M, Ho CW, Wang GJ, Newman AH, Heidbreder CA, Ashby CR Jr, Gardner EL, Volkow ND (2008) The effects of two highly selective dopamine D3 receptor antagonists (SB-277011A and NGB-2904) on food self-administration in a rodent model of obesity. Pharmacol Biochem Behav 89:499-507
92. Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M, Laruelle M, Rabiner EA, Gunn RN (2011) Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. NeuroImage 54:264-277
93. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614
94. Vengeliene V, Leonardi-Essmann F, Perreau-Lenz S, Gebicke-Haerter P, Drescher K, Gross G, Spanagel R (2006) The dopamine D3 receptor plays an essential role in alcohol-seeking and relapse. FASEB J 20:2223-2233
95. Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ, Dewey SL, Wolf AP (1993) Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14:169-177
96. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD, Dewey SL, Pappas N (1997) Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386:830-833
97. Volkow ND, Fowler JS, Wang GJ, Goldstein RZ (2002) Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Neurobiol Learn Mem 78:610-624
98. 3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 22:9595-9603
99. Watson DJ, Loiseau F, Ingallinesi M, Millan MJ, Marsden CA, Fone KC (2012a) Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. Neuropsychopharmacology 37:770-786
100. Watson DJ, Marsden CA, Millan MJ, Fone KC (2012b) Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. Int J Neuropsychopharmacol 15:471-484
101. Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D, Houle S, Seeman P, Ginovart N (2005) Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48:4153-4160
102. Wise RA (2004) Dopamine, learning and motivation. Nat Rev Neurosci 5:483-494
103. Xi ZX, Gardner EL (2007) Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev 13:240-259
104. 3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacol (Berl) 176:57-65
105. Xi ZX, Gilbert JG, Pak AC, Ashby CR Jr, Heidbreder CA, Gardner EL (2005) Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost/variable-payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci 21:3427-3438
106. Xi ZX, Newman AH, Gilbert JG, Pak AC, Peng XQ, Ashby CR Jr, Gitajn L, Gardner EL (2006) The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 31:1393-1405
107. Xing B, Meng X, Wei S, Li S (2010) Influence of dopamine D3 receptor knockout on age-related decline of spatial memory. Neurosci Lett 481:149-153
108. Yuan J, Chen X, Brodbeck R, Primus R, Braun J, Wasley JW, Thurkauf A (1998) NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists. Bioorg Med Chem Lett 8:2715-2718
109. 1 dopamine receptors. Nature 347:76-80